The translational gap in CNS drug discovery drives high clinical failure rates. Transitioning from traditional 2D assays to human iPSC-derived 3D disease models and automated phenotypic screening offers a scalable path to identify robust neuro-therapeutic candidates.
The development of therapeutics for central nervous system (CNS) disorders, particularly neurodegenerative conditions...
Bangla